PMC8407559_01
Study flowchart.. * Negative or missing cultures at baseline were excluded.
pone.0256464.g001.jpg
PMC8407559_02_pone.0256464.g001.jpg
pone.0256464.g001
Following BMA, the most parsimonious model retained age, fosfomycin treatment, and recruitment site (TA) as independent predictors for clinical failure, and age for microbiologic failure (S2-S4 Figs in S1 Appendix). In patients >52 years old, nitrofurantoin remained superior to fosfomycin in terms of clinical, but not microbiologic, success (Table 2, S1 Fig in S1 Appendix).
Variation of clinical and microbiological failure across different age groups and treatment groups.
pone.0256464.g002.jpg
PMC8407559_01_pone.0256464.g002.jpg
pone.0256464.g002
Women who experienced clinical or microbiologic failure by day 28 were on average 10 years older (mean age 56.8 +-22.5 and 58.0 +-20.8 versus 45.8 +-19.6 and 47.2 +-20.7 years, respectively, [p<0.001]); the same pattern was seen in the E. coli subgroup (Fig 2, S1 Fig in S1 Appendix).
PMC8407559_02
Study flowchart.. * Negative or missing cultures at baseline were excluded.
pone.0256464.g001.jpg
PMC8407559_02_pone.0256464.g001.jpg
pone.0256464.g001
Following BMA, the most parsimonious model retained age, fosfomycin treatment, and recruitment site (TA) as independent predictors for clinical failure, and age for microbiologic failure (S2-S4 Figs in S1 Appendix). In patients >52 years old, nitrofurantoin remained superior to fosfomycin in terms of clinical, but not microbiologic, success (Table 2, S1 Fig in S1 Appendix).
Bacterial population isolated from urinary culture among different age groups.
pone.0256464.g003.jpg
PMC8407559_02_pone.0256464.g003.jpg
pone.0256464.g003
No significant variation was observed for these pathogens across different age categories (Fig 3).